545 related articles for article (PubMed ID: 32016960)
1. Long non-coding RNA UCA1 promotes the progression of paclitaxel resistance in ovarian cancer by regulating the miR-654-5p/SIK2 axis.
Li ZY; Wang XL; Dang Y; Zhu XZ; Zhang YH; Cai BX; Zheng L
Eur Rev Med Pharmacol Sci; 2020 Jan; 24(2):591-603. PubMed ID: 32016960
[TBL] [Abstract][Full Text] [Related]
2. Overexpression of circ_CELSR1 facilitates paclitaxel resistance of ovarian cancer by regulating miR-149-5p/SIK2 axis.
Wei S; Qi L; Wang L
Anticancer Drugs; 2021 Jun; 32(5):496-507. PubMed ID: 33735118
[TBL] [Abstract][Full Text] [Related]
3. UCA1 confers paclitaxel resistance to ovarian cancer through miR-129/ABCB1 axis.
Wang J; Ye C; Liu J; Hu Y
Biochem Biophys Res Commun; 2018 Jul; 501(4):1034-1040. PubMed ID: 29777711
[TBL] [Abstract][Full Text] [Related]
4. Long noncoding RNA MEG3 suppresses cell proliferation, migration and invasion, induces apoptosis and paclitaxel-resistance via miR-4513/PBLD axis in breast cancer cells.
Zhu M; Wang F; Mi H; Li L; Wang J; Han M; Gu Y
Cell Cycle; 2020 Dec; 19(23):3277-3288. PubMed ID: 33121324
[TBL] [Abstract][Full Text] [Related]
5. Long noncoding RNA UCA1 regulates CCR7 expression to promote tongue squamous cell carcinoma progression by sponging miR-138-5p.
Shi TT; Li R; Zhao L
Neoplasma; 2020 Nov; 67(6):1256-1265. PubMed ID: 32749849
[TBL] [Abstract][Full Text] [Related]
6. Circ-RNF111 contributes to paclitaxel resistance in breast cancer by elevating E2F3 expression via miR-140-5p.
Zang H; Li Y; Zhang X; Huang G
Thorac Cancer; 2020 Jul; 11(7):1891-1903. PubMed ID: 32445273
[TBL] [Abstract][Full Text] [Related]
7. Downregulation of circNRIP1 Suppresses the Paclitaxel Resistance of Ovarian Cancer via Regulating the miR-211-5p/HOXC8 Axis.
Li M; Cai J; Han X; Ren Y
Cancer Manag Res; 2020; 12():9159-9171. PubMed ID: 33061608
[TBL] [Abstract][Full Text] [Related]
8. SNHG5 enhances Paclitaxel sensitivity of ovarian cancer cells through sponging miR-23a.
Lin H; Shen L; Lin Q; Dong C; Maswela B; Illahi GS; Wu X
Biomed Pharmacother; 2020 Mar; 123():109711. PubMed ID: 31884343
[TBL] [Abstract][Full Text] [Related]
9. Circ_0025033 deficiency suppresses paclitaxel resistance and malignant development of paclitaxel-resistant ovarian cancer cells by modulating the miR-532-3p/FOXM1 network.
Huang H; Yan L; Zhong J; Hong L; Zhang N; Luo X
Immunopharmacol Immunotoxicol; 2022 Apr; 44(2):275-286. PubMed ID: 35196944
[TBL] [Abstract][Full Text] [Related]
10. Upregulation of miR-874-3p and miR-874-5p inhibits epithelial ovarian cancer malignancy via SIK2.
Xia B; Lin M; Dong W; Chen H; Li B; Zhang X; Hou Y; Lou G
J Biochem Mol Toxicol; 2018 Aug; 32(8):e22168. PubMed ID: 30004169
[TBL] [Abstract][Full Text] [Related]
11. Knockdown of lncRNA CCAT1 enhances sensitivity of paclitaxel in prostate cancer via regulating miR-24-3p and FSCN1.
Li X; Han X; Wei P; Yang J; Sun J
Cancer Biol Ther; 2020 May; 21(5):452-462. PubMed ID: 32089062
[TBL] [Abstract][Full Text] [Related]
12. LINC-PINT suppresses tumour cell proliferation, migration and invasion through targeting miR-374a-5p in ovarian cancer.
Hao T; Huang S; Han F
Cell Biochem Funct; 2020 Dec; 38(8):1089-1099. PubMed ID: 32638404
[TBL] [Abstract][Full Text] [Related]
13. Long noncoding RNA CASC2 promotes paclitaxel resistance in breast cancer through regulation of miR-18a-5p/CDK19.
Zheng P; Dong L; Zhang B; Dai J; Zhang Y; Wang Y; Qin S
Histochem Cell Biol; 2019 Oct; 152(4):281-291. PubMed ID: 31352515
[TBL] [Abstract][Full Text] [Related]
14. LncRNA PRKCQ-AS1 regulates paclitaxel resistance in triple-negative breast cancer cells through miR-361-5p/PIK3C3 mediated autophagy.
Zheng S; Fu W; Huang Q; Zhou J; Lu K; Gu J; Ma R; Guo G
Clin Exp Pharmacol Physiol; 2023 Jun; 50(6):431-442. PubMed ID: 36732923
[TBL] [Abstract][Full Text] [Related]
15. LncRNA AFAP1-AS1 modulates the sensitivity of paclitaxel-resistant prostate cancer cells to paclitaxel via miR-195-5p/FKBP1A axis.
Leng W; Liu Q; Zhang S; Sun D; Guo Y
Cancer Biol Ther; 2020 Nov; 21(11):1072-1080. PubMed ID: 33138677
[TBL] [Abstract][Full Text] [Related]
16. Repression of lncRNA PART1 attenuates ovarian cancer cell viability, migration and invasion through the miR-503-5p/FOXK1 axis.
Li B; Lou G; Zhang J; Cao N; Yu X
BMC Cancer; 2022 Jan; 22(1):124. PubMed ID: 35100978
[TBL] [Abstract][Full Text] [Related]
17. Circ_0078607 inhibits the progression of ovarian cancer via regulating the miR-32-5p/SIK1 network.
Jin Y; Wang H
J Ovarian Res; 2022 Jan; 15(1):3. PubMed ID: 34983607
[TBL] [Abstract][Full Text] [Related]
18. lncRNA-PRLB Confers Paclitaxel Resistance of Ovarian Cancer Cells by Regulating RSF1/NF-κB Signaling Pathway.
Zhao Y; Hong L
Cancer Biother Radiopharm; 2021 Mar; 36(2):202-210. PubMed ID: 33156701
[No Abstract] [Full Text] [Related]
19. MiR-21-5p enhances the progression and paclitaxel resistance in drug-resistant breast cancer cell lines by targeting PDCD4.
Tao L; Wu YQ; Zhang SP
Neoplasma; 2019 Sep; 66(5):746-755. PubMed ID: 31169019
[TBL] [Abstract][Full Text] [Related]
20. miR-145-5p attenuates paclitaxel resistance and suppresses the progression in drug-resistant breast cancer cell lines.
Guan X; Guan Y
Neoplasma; 2020 Sep; 67(5):972-981. PubMed ID: 32412771
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
